CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net income	$ 54,485	$ 106,770
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	66,665	50,770
Non-cash interest expense	3,888	552
Non-cash stock compensation expense	25,983	14,764
Non-cash income tax (benefit) expense	813	(164)
Non-cash amortization on investments	3,620	7,273
Realized loss on sale of investments	40	0
Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:
Restricted cash	71,530	17,987
Accounts receivable, net	(19,492)	(19,231)
Pharmaceutical inventory	8,710	(1,680)
Other assets	(22,378)	(9,781)
Accounts payable and accrued liabilities	(28,461)	6,685
Medical claims payable and other medical liabilities	39,940	16,144
Tax contingencies	(15,179)	(22,981)
Deferred credits and other long-term liabilities	3,940	2,221
Other	138	1,953
Net cash provided by operating activities	194,242	171,282
Cash flows from investing activities:
Capital expenditures	(50,597)	(42,091)
Acquisitions and investments in businesses, net of cash acquired	(132,210)
Purchase of investments	(216,958)	(235,946)
Maturity of investments	220,191	233,723
Other		(7,900)
Net cash used in investing activities	(179,574)	(52,214)
Cash flows from financing activities:
Proceeds from issuance of debt	250,000
Payments to acquire treasury stock	(139,316)	(49,462)
Proceeds from exercise of stock options and warrants	41,685	24,548
Payments on capital lease obligations	(2,606)	(2,310)
Other	655	484
Net cash (used in) provided by financing activities	150,418	(26,740)
Net increase in cash and cash equivalents	165,086	92,328
Cash and cash equivalents at beginning of period	203,187	189,464
Cash and cash equivalents at end of period	368,273	281,792
Non-cash investing activities:
Property and equipment acquired under capital leases	$ 216	$ 29,323